id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-6737-0009,FDA,FDA-2026-P-6737,Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:46Z,,0,0,09000064b932a303
FDA-2026-P-6737-0012,FDA,FDA-2026-P-6737,Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:55Z,,0,0,09000064b932a306
FDA-2026-P-6737-0003,FDA,FDA-2026-P-6737,Reference 1 - Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:26Z,,0,0,09000064b932a273
FDA-2026-P-6737-0008,FDA,FDA-2026-P-6737,Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:43Z,,0,0,09000064b932a302
FDA-2026-P-6737-0043,FDA,FDA-2026-P-6737,Reference 41 - Long-Term Treatment with Gadopentetic Acid or Gadodiamide,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:44Z,,0,0,09000064b932a33d
FDA-2026-P-6737-0040,FDA,FDA-2026-P-6737,Reference 38 - Ultrastructural Evidence of Dermal Gadolinium Deposits,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:34Z,,0,0,09000064b932a33a
FDA-2026-P-6737-0045,FDA,FDA-2026-P-6737,Reference 43 - An initial investigation of serum cytokine levels in patients with gadolinium retention,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:50Z,,0,0,09000064b932a33f
FDA-2026-P-6737-0030,FDA,FDA-2026-P-6737,Reference 28 - Skin-Related Adverse Reactions in Gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:56Z,,0,0,09000064b932a326
FDA-2026-P-6737-0021,FDA,FDA-2026-P-6737,Reference 19 -  Gadolinium-based contrast agent toxicity,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:25Z,,0,0,09000064b932a311
FDA-2026-P-6737-0024,FDA,FDA-2026-P-6737,Reference 22 -  Gadolinium deposition in bone tissues after contrast-enhanced,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:37Z,,0,0,09000064b932a314
FDA-2026-P-6737-0044,FDA,FDA-2026-P-6737,Reference 42 - Altered Functional Mitochondrial Protein Levels in Plasma,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:47Z,,0,0,09000064b932a33e
FDA-2026-P-6737-0015,FDA,FDA-2026-P-6737,Reference 13 - Prepubertal exposure to gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:05Z,,0,0,09000064b932a309
FDA-2026-P-6737-0018,FDA,FDA-2026-P-6737,Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:15Z,,0,0,09000064b932a30e
FDA-2026-P-6737-0037,FDA,FDA-2026-P-6737,Reference 35 - The Impact of Gadolinium on Quantitative Myelin Metrics,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:23Z,,0,0,09000064b932a337
FDA-2026-P-6737-0005,FDA,FDA-2026-P-6737,Reference 3 - Gadolinium retention effect on macrophages,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:32Z,,0,0,09000064b932a275
FDA-2026-P-6737-0041,FDA,FDA-2026-P-6737,Reference 39 - Delineating toxicity mechanisms associated with MRI contrast,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:37Z,,0,0,09000064b932a33b
FDA-2026-P-6737-0023,FDA,FDA-2026-P-6737,Reference 21 -  Influence blocking by Gadolinium in Calcium Diffusion,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:33Z,,0,0,09000064b932a313
FDA-2026-P-6737-0007,FDA,FDA-2026-P-6737,Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:40Z,,0,0,09000064b932a301
FDA-2026-P-6737-0010,FDA,FDA-2026-P-6737,Reference 8 - Repeated gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:50Z,,0,0,09000064b932a304
FDA-2026-P-6737-0006,FDA,FDA-2026-P-6737,Reference 4 - Gadolinium accelerates the migration of astrocyte via integrin signaling pathway,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-07-12T11:12:37Z,,0,0,09000064b932a300
FDA-2026-P-6737-0019,FDA,FDA-2026-P-6737,Reference 17 - Effects of Salicylate and Lanthanides on Outer Hair Cell Motility,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:19Z,,0,0,09000064b932a30f
FDA-2026-P-6737-0011,FDA,FDA-2026-P-6737,Reference 9 - Gadolinium Mitochondrial Toxicity,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:52Z,,0,0,09000064b932a305
FDA-2026-P-6737-0017,FDA,FDA-2026-P-6737,Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:11Z,,0,0,09000064b932a30d
FDA-2026-P-6737-0028,FDA,FDA-2026-P-6737,Reference 26 - Neurotoxicity from intrathecal gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:49Z,,0,0,09000064b932a324
FDA-2026-P-6737-0031,FDA,FDA-2026-P-6737,Reference 29 - Acute lung injury following gadolinium contrast,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:00Z,,0,0,09000064b932a327
FDA-2026-P-6737-0033,FDA,FDA-2026-P-6737,Reference 31 - Gadolinium-based contrast agent-induced neurotoxicity seeing is believing,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:07Z,,0,0,09000064b932a329
FDA-2026-P-6737-0026,FDA,FDA-2026-P-6737,Reference 24 -  Effects of Gadolinium-Based MRI Contrast,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:43Z,,0,0,09000064b932a322
FDA-2026-P-6737-0004,FDA,FDA-2026-P-6737,Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:30Z,,0,0,09000064b932a274
FDA-2026-P-6737-0001,FDA,FDA-2026-P-6737,Citizen Petition from Regina Sutton,Other,Citizen Petition,2026-06-15T04:00:00Z,2026,6,2026-06-15T04:00:00Z,,2026-06-15T20:27:13Z,,1,0,09000064b9329d15
FDA-2026-P-6737-0022,FDA,FDA-2026-P-6737,Reference 20 -  Human Hair as a Possible Surrogate Marker of Retained Tissue,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:30Z,,0,0,09000064b932a312
FDA-2026-P-6737-0013,FDA,FDA-2026-P-6737,Reference 11 - On the interaction of muscle actin with gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:27:58Z,,0,0,09000064b932a307
FDA-2026-P-6737-0016,FDA,FDA-2026-P-6737,Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:09Z,,0,0,09000064b932a30c
FDA-2026-P-6737-0036,FDA,FDA-2026-P-6737,Reference 34 - Immediate Adverse Reactions to Gandolinium-Based MR Contrast Media,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:20Z,,0,0,09000064b932a336
FDA-2026-P-6737-0042,FDA,FDA-2026-P-6737,Reference 40 - The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:40Z,,0,0,09000064b932a33c
FDA-2026-P-6737-0014,FDA,FDA-2026-P-6737,Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:02Z,,0,0,09000064b932a308
FDA-2026-P-6737-0002,FDA,FDA-2026-P-6737,Acknowledgement Letter from FDA DMB to Regina Sutton,Other,Acknowledgement Letter/Receipt,2026-06-15T04:00:00Z,2026,6,2026-06-15T04:00:00Z,,2026-06-15T20:27:18Z,,0,0,09000064b9329d18
FDA-2026-P-6737-0027,FDA,FDA-2026-P-6737,Reference 25 - INDUCTION OF EXPRESSION OF PROFIBROTIC CYTOKINES,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:46Z,,0,0,09000064b932a323
FDA-2026-P-6737-0020,FDA,FDA-2026-P-6737,Reference 18 -  Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:22Z,,0,0,09000064b932a310
FDA-2026-P-6737-0034,FDA,FDA-2026-P-6737,Reference 32 - Caught in the act Allergic-like reaction to,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:10Z,,0,0,09000064b932a32a
FDA-2026-P-6737-0038,FDA,FDA-2026-P-6737,Reference 36 - Effects of gadolinium,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:26Z,,0,0,09000064b932a338
FDA-2026-P-6737-0029,FDA,FDA-2026-P-6737,Reference 27 - Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:52Z,,0,0,09000064b932a325
FDA-2026-P-6737-0035,FDA,FDA-2026-P-6737,Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent.,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:16Z,,0,0,09000064b932a32b
FDA-2026-P-6737-0039,FDA,FDA-2026-P-6737,Reference 37 - Gadolinium Contrast Agent Deposition in Children,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:30Z,,0,0,09000064b932a339
FDA-2026-P-6737-0025,FDA,FDA-2026-P-6737,Reference 23 -  Assessment of gadolinium and iodine concentrations in kidney stones,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:28:40Z,,0,0,09000064b932a315
FDA-2026-P-6737-0032,FDA,FDA-2026-P-6737,Reference 30 - Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T20:29:03Z,,0,0,09000064b932a328